1h Free Analyst Time
The chronic kidney disease (CKD) drugs market is forecasted to grow by USD 3.81 bn during 2023-2028, accelerating at a CAGR of 4.77% during the forecast period. The report on the chronic kidney disease (CKD) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of CKD globally, increase in healthcare expenditure globally, and growing awareness about need for early detection and diagnosis of CKD.
The chronic kidney disease (CKD) drugs market is segmented as below:
By Drug Class
- Erythropoietin stimulating agents
- Calcium channel blockers
- Phosphate binders
- ACE inhibitors
- Others
By Route Of Administration
- Oral
- Subcutaneous
- Intravenous
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the chronic kidney disease (CKD) drugs market covers the following areas:
- Chronic kidney disease (CKD) drugs market sizing
- Chronic kidney disease (CKD) drugs market forecast
- Chronic kidney disease (CKD) drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global chronic kidney disease (CKD) drugs market: Abbott Laboratories, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cara Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Horizon Therapeutics Plc, Johnson and Johnson, Kissei Pharmaceutical Co. Ltd., Novartis AG, OPKO Health Inc., Pfizer Inc., Pharmacosmos AS, Rockwell Medical Inc., Sanofi SA, Shield Therapeutics plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Xenetic Biosciences Inc., Zydus Lifesciences Ltd., Ardelyx Inc., and Aurinia Pharmaceuticals Inc..Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is growing number of drug approvals for CKD treatment.`
According to the report, one of the major drivers for this market is the rising prevalence of CKD globally.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Akebia Therapeutics Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Cara Therapeutics Inc.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- FibroGen Inc.
- Horizon Therapeutics Plc
- Johnson and Johnson
- Kissei Pharmaceutical Co. Ltd.
- Novartis AG
- OPKO Health Inc.
- Pfizer Inc.
- Pharmacosmos AS
- Rockwell Medical Inc.
- Sanofi SA
- Shield Therapeutics plc
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Xenetic Biosciences Inc.
- Zydus Lifesciences Ltd.
- Ardelyx Inc.
- Aurinia Pharmaceuticals Inc.
